Medical pharmacology review updated 10 November 2026. Educational material; local labeling, emergency protocols and clinical toxicology guidance take precedence in individual patient care.
Overview and corrected chemistry
Dimercaprol, historically called British anti-Lewisite (BAL), is a sulfur-containing chelator whose chemical structure is 2,3-dimercapto-1-propanol (C3H8OS2). It is not 3,3′-dithiodipropionic acid bis(2-ethylhexyl ester), as the earlier monograph incorrectly stated. Its adjacent sulfhydryl groups bind selected toxic metals, reducing interactions with critical tissue enzymes. Because dimercaprol itself can cause significant toxicity, treatment requires poison-center or clinical toxicology supervision [1,2].
Mechanism and pharmacologic principles
Many toxic metals bind sulfhydryl groups on cellular enzymes and structural proteins. Dimercaprol offers thiol groups that form complexes with accessible metal ions, facilitating their redistribution and excretion under appropriate circumstances. Chelation benefit depends on metal species, time since exposure and organ function; it does not mechanically reverse tissue damage that has already occurred. Some dimercaprol-metal complexes are more harmful than the unchelated metal [1,2].
Administration: intramuscular in oil
The 2026 US BAL in Oil product is an intramuscular injection containing dimercaprol in peanut oil, at 100 mg/mL. It is not a water-soluble IV infusion or an aqueous solution; the prior monograph was dangerously inaccurate about formulation and route. Deep IM administration can be painful, and the preparation is contraindicated in patients with peanut allergy under the current US label. Drug preparation, schedule and concurrent chelation depend on poison type and urgency [2].
2026 labeled indications and restrictions
The FDA label indicates BAL in Oil for arsenic or gold poisoning, acute mercury poisoning when begun within two hours of ingestion, and acute lead poisoning when used with edetate calcium disodium. It is not effective for chronic mercury or lead poisoning. It is not indicated for poisoning with iron, cadmium or selenium because toxic complexes may worsen kidney injury; other metals have additional evidence limitations. Choice of chelator is patient- and metal-specific [2].
Toxicity, contraindications and monitoring
Dimercaprol can cause headache, nausea/vomiting, hypertension, tachycardia, chest discomfort, burning sensations, sweating, painful injection sites and renal toxicity; serious reactions are dose-related. Hepatic impairment and acute kidney injury require special caution or contraindicate use according to clinical context. During treatment assess vitals, kidney/liver function, urine output, symptoms and metal concentrations when appropriate. Do not use empirically for nonspecific symptoms or unverified ‘metal burden’ claims [1,2].
Lead poisoning and antidotal selection
For clinically important lead encephalopathy, dimercaprol may be combined with calcium disodium EDTA under expert protocols. Correct chelator identification matters: disodium EDTA is not an interchangeable substitute for calcium disodium EDTA and can cause severe hypocalcemia. Occupational/environmental exposure cessation, decontamination and supportive management remain essential [1,2].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- US Food and Drug Administration. BAL in Oil (dimercaprol injection): prescribing information, 2026. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/005939s018lbl.pdf
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.